Pagibaximab

Drug Profile

Pagibaximab

Alternative Names: A110; BSYX-A110; HU 96110

Latest Information Update: 26 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Molecular Evolution; Biosynexus
  • Developer Biosynexus
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Lipoteichoic acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Staphylococcal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 07 Dec 2010 Biosynexus completes enrolment in its phase II/III trial for Staphylococcal infections in USA (MAB-N007)
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 13 Jun 2006 This monoclonal antibody is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top